Shenlian Biotech announced that the phase II clinical study of the biological-like drug UB-221 injection independently developed by the company holding Sun Company to treat chronic spontaneous urticaria reached the main end point and achieved positive top-line results. The study included 145 medium to severe subjects. The response rate for all UB-221 dose groups was significantly higher than that of the placebo group, and the overall tolerability was good, supporting the promotion of phase III clinical research. This matter is not expected to have a significant impact on the company's performance in the short term. It is still necessary to complete procedures such as phase III clinical trials and new drug marketing applications. There is uncertainty about innovative drug development.

Shenlian Biotech announced that the phase II clinical study of the biological-like drug UB-221 injection independently developed by the company holding Sun Company to treat chronic spontaneous urticaria reached the main end point and achieved positive top-line results. The study included 145 medium to severe subjects. The response rate for all UB-221 dose groups was significantly higher than that of the placebo group, and the overall tolerability was good, supporting the promotion of phase III clinical research. This matter is not expected to have a significant impact on the company's performance in the short term. It is still necessary to complete procedures such as phase III clinical trials and new drug marketing applications. There is uncertainty about innovative drug development.